Ondine Biomedical (OBI) Competitors

C$15.00 0.00 (0.00%)

As of 05:05 PM Eastern

OBI vs. ABC, GNS, ONT, OXB, and ERGO

Should you buy Ondine Biomedical stock or one of its competitors? MarketBeat compares Ondine Biomedical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ondine Biomedical include Abcam (ABC), Genus (GNS), Oxford Nanopore Technologies (ONT), Oxford Biomedica (OXB), and Ergomed (ERGO). These companies are all part of the "biotechnology" industry.

How does Ondine Biomedical compare to Abcam?

Ondine Biomedical (LON:OBI) and Abcam (LON:ABC) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, risk, valuation, analyst recommendations, profitability, media sentiment and earnings.

28.8% of Ondine Biomedical shares are held by institutional investors. 37.4% of Ondine Biomedical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Abcam has a net margin of 0.00% compared to Ondine Biomedical's net margin of -1,127.55%. Abcam's return on equity of 0.00% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ondine Biomedical	-1,127.55%	-506.43%	-159.71%
Abcam	N/A	N/A	N/A

In the previous week, Ondine Biomedical had 1 more articles in the media than Abcam. MarketBeat recorded 1 mentions for Ondine Biomedical and 0 mentions for Abcam. Ondine Biomedical's average media sentiment score of 0.00 equaled Abcam'saverage media sentiment score.

Company	Overall Sentiment
Ondine Biomedical	Neutral
Abcam	Neutral

Abcam has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ondine Biomedical	C$2.05M	3,803.45	-C$424.66K	-C$7.00	N/A
Abcam	£350.40M	0.00	N/A	£0.06	N/A

Summary

Abcam beats Ondine Biomedical on 6 of the 9 factors compared between the two stocks.

How does Ondine Biomedical compare to Genus?

Genus (LON:GNS) and Ondine Biomedical (LON:OBI) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment and analyst recommendations.

Genus has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genus	£672M	2.37	£7.87M	£71.00	33.77
Ondine Biomedical	C$2.05M	3,803.45	-C$424.66K	-C$7.00	N/A

53.1% of Genus shares are held by institutional investors. Comparatively, 28.8% of Ondine Biomedical shares are held by institutional investors. 0.7% of Genus shares are held by insiders. Comparatively, 37.4% of Ondine Biomedical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Genus presently has a consensus target price of GBX 3,216.67, indicating a potential upside of 34.14%. Given Genus' stronger consensus rating and higher possible upside, research analysts clearly believe Genus is more favorable than Ondine Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00
Ondine Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Genus had 2 more articles in the media than Ondine Biomedical. MarketBeat recorded 3 mentions for Genus and 1 mentions for Ondine Biomedical. Genus' average media sentiment score of 0.45 beat Ondine Biomedical's score of 0.00 indicating that Genus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genus	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ondine Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Genus has a beta of 0.895, suggesting that its stock price is 11% less volatile than the broader market. Comparatively, Ondine Biomedical has a beta of 0.273, suggesting that its stock price is 73% less volatile than the broader market.

Genus has a net margin of 7.07% compared to Ondine Biomedical's net margin of -1,127.55%. Genus' return on equity of 9.70% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genus	7.07%	9.70%	3.31%
Ondine Biomedical	-1,127.55%	-506.43%	-159.71%

Summary

Genus beats Ondine Biomedical on 14 of the 16 factors compared between the two stocks.

How does Ondine Biomedical compare to Oxford Nanopore Technologies?

Ondine Biomedical (LON:OBI) and Oxford Nanopore Technologies (LON:ONT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

28.8% of Ondine Biomedical shares are held by institutional investors. Comparatively, 18.9% of Oxford Nanopore Technologies shares are held by institutional investors. 37.4% of Ondine Biomedical shares are held by company insiders. Comparatively, 2.3% of Oxford Nanopore Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Oxford Nanopore Technologies has a net margin of -64.85% compared to Ondine Biomedical's net margin of -1,127.55%. Oxford Nanopore Technologies' return on equity of -29.43% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ondine Biomedical	-1,127.55%	-506.43%	-159.71%
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%

Ondine Biomedical has higher earnings, but lower revenue than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ondine Biomedical	C$2.05M	3,803.45	-C$424.66K	-C$7.00	N/A
Oxford Nanopore Technologies	£223.90M	5.16	-£175.21M	-£15.10	N/A

Ondine Biomedical has a beta of 0.273, meaning that its share price is 73% less volatile than the broader market. Comparatively, Oxford Nanopore Technologies has a beta of 0.869, meaning that its share price is 13% less volatile than the broader market.

In the previous week, Oxford Nanopore Technologies had 1 more articles in the media than Ondine Biomedical. MarketBeat recorded 2 mentions for Oxford Nanopore Technologies and 1 mentions for Ondine Biomedical. Oxford Nanopore Technologies' average media sentiment score of 1.23 beat Ondine Biomedical's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ondine Biomedical	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oxford Nanopore Technologies	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oxford Nanopore Technologies has a consensus price target of GBX 218.60, indicating a potential upside of 83.89%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, analysts plainly believe Oxford Nanopore Technologies is more favorable than Ondine Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ondine Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80

Summary

Oxford Nanopore Technologies beats Ondine Biomedical on 10 of the 16 factors compared between the two stocks.

How does Ondine Biomedical compare to Oxford Biomedica?

Ondine Biomedical (LON:OBI) and Oxford Biomedica (LON:OXB) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, media sentiment, profitability, dividends, valuation, institutional ownership and earnings.

Oxford Biomedica has a net margin of -17.85% compared to Ondine Biomedical's net margin of -1,127.55%. Oxford Biomedica's return on equity of -48.56% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ondine Biomedical	-1,127.55%	-506.43%	-159.71%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Ondine Biomedical has a beta of 0.273, indicating that its share price is 73% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.095, indicating that its share price is 10% more volatile than the broader market.

Oxford Biomedica has a consensus target price of GBX 687, suggesting a potential upside of 16.64%. Given Oxford Biomedica's stronger consensus rating and higher possible upside, analysts plainly believe Oxford Biomedica is more favorable than Ondine Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ondine Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Biomedica	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86

Ondine Biomedical has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ondine Biomedical	C$2.05M	3,803.45	-C$424.66K	-C$7.00	N/A
Oxford Biomedica	£168.74M	4.22	-£143.51M	-£26.92	N/A

In the previous week, Ondine Biomedical had 1 more articles in the media than Oxford Biomedica. MarketBeat recorded 1 mentions for Ondine Biomedical and 0 mentions for Oxford Biomedica. Ondine Biomedical's average media sentiment score of 0.00 equaled Oxford Biomedica'saverage media sentiment score.

Company	Overall Sentiment
Ondine Biomedical	Neutral
Oxford Biomedica	Neutral

28.8% of Ondine Biomedical shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 37.4% of Ondine Biomedical shares are owned by company insiders. Comparatively, 25.9% of Oxford Biomedica shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Oxford Biomedica beats Ondine Biomedical on 9 of the 15 factors compared between the two stocks.

How does Ondine Biomedical compare to Ergomed?

Ergomed (LON:ERGO) and Ondine Biomedical (LON:OBI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.

In the previous week, Ondine Biomedical had 1 more articles in the media than Ergomed. MarketBeat recorded 1 mentions for Ondine Biomedical and 0 mentions for Ergomed. Ergomed's average media sentiment score of 0.00 equaled Ondine Biomedical'saverage media sentiment score.

Company	Overall Sentiment
Ergomed	Neutral
Ondine Biomedical	Neutral

Ergomed has a net margin of 9.87% compared to Ondine Biomedical's net margin of -1,127.55%. Ergomed's return on equity of 18.08% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ergomed	9.87%	18.08%	10.16%
Ondine Biomedical	-1,127.55%	-506.43%	-159.71%

71.1% of Ergomed shares are held by institutional investors. Comparatively, 28.8% of Ondine Biomedical shares are held by institutional investors. 18.2% of Ergomed shares are held by insiders. Comparatively, 37.4% of Ondine Biomedical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Ergomed has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ergomed	£152.09M	0.00	£15M	£0.29	N/A
Ondine Biomedical	C$2.05M	3,803.45	-C$424.66K	-C$7.00	N/A

Ergomed has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market. Comparatively, Ondine Biomedical has a beta of 0.273, suggesting that its share price is 73% less volatile than the broader market.

Summary

Ergomed beats Ondine Biomedical on 9 of the 11 factors compared between the two stocks.

Get Ondine Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBI vs. The Competition

Export

Metric	Ondine Biomedical	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	C$7.79B	C$461.30M	C$6.28B	C$2.79B
Dividend Yield	N/A	3.87%	2.80%	6.17%
P/E Ratio	-2.14	3.83	20.74	365.29
Price / Sales	3,803.45	7,349.38	528.91	87,514.55
Price / Cash	1.99	13.13	43.09	27.89
Price / Book	1,737.19	82.86	9.90	7.58
Net Income	-C$424.66K	-C$96.07M	C$3.55B	C$5.89B
7 Day Performance	3.45%	-0.13%	-0.30%	0.20%
1 Month Performance	30.43%	0.13%	-2.34%	0.88%
1 Year Performance	76.47%	70.43%	30.90%	82.73%

Ondine Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBI Ondine Biomedical	N/A	C$15.00 flat	N/A	+76.5%	C$7.79B	C$2.05M	N/A	N/A
ABC Abcam	N/A	N/A	N/A	N/A	£2.81B	£350.40M	20,433.33	1,650	Gap Up High Trading Volume
GNS Genus	3.487 of 5 stars	GBX 2,388.92 +1.1%	GBX 3,216.67 +34.6%	+12.7%	£1.60B	£672M	33.65	480	News Coverage High Trading Volume
ONT Oxford Nanopore Technologies	2.902 of 5 stars	GBX 121.66 -1.6%	GBX 218.60 +79.7%	-0.3%	£1.17B	£223.90M	N/A	1,281	Positive News
OXB Oxford Biomedica	N/A	GBX 618 -0.2%	GBX 687 +11.2%	+99.3%	£747.28M	£168.74M	N/A	891	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:OBI) was last updated on 5/20/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ondine Biomedical (OBI) Competitors

OBI vs. ABC, GNS, ONT, OXB, and ERGO

How does Ondine Biomedical compare to Abcam?

Summary

How does Ondine Biomedical compare to Genus?

Summary

How does Ondine Biomedical compare to Oxford Nanopore Technologies?

Summary

How does Ondine Biomedical compare to Oxford Biomedica?

Summary

How does Ondine Biomedical compare to Ergomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBI vs. The Competition

Ondine Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ondine Biomedical (OBI) Competitors

OBI vs. ABC, GNS, ONT, OXB, and ERGO

How does Ondine Biomedical compare to Abcam?

Do insiders & institutionals have more ownership in OBI or ABC?

Is OBI or ABC more profitable?

Does the media prefer OBI or ABC?

Which has preferable valuation & earnings, OBI or ABC?

Summary

How does Ondine Biomedical compare to Genus?

Which has better valuation & earnings, GNS or OBI?

Do institutionals & insiders believe in GNS or OBI?

Do analysts recommend GNS or OBI?

Does the media favor GNS or OBI?

Which has more risk and volatility, GNS or OBI?

Is GNS or OBI more profitable?

Summary

How does Ondine Biomedical compare to Oxford Nanopore Technologies?

Do insiders & institutionals have more ownership in OBI or ONT?

Is OBI or ONT more profitable?

Which has stronger earnings & valuation, OBI or ONT?

Which has more risk and volatility, OBI or ONT?

Does the media prefer OBI or ONT?

Do analysts prefer OBI or ONT?

Summary

How does Ondine Biomedical compare to Oxford Biomedica?

Is OBI or OXB more profitable?

Which has more risk and volatility, OBI or OXB?

Do analysts recommend OBI or OXB?

Which has better earnings and valuation, OBI or OXB?

Does the media refer more to OBI or OXB?

Do institutionals & insiders hold more shares of OBI or OXB?

Summary

How does Ondine Biomedical compare to Ergomed?

Does the media favor ERGO or OBI?

Is ERGO or OBI more profitable?

Do institutionals and insiders believe in ERGO or OBI?

Which has better earnings & valuation, ERGO or OBI?

Which has more volatility and risk, ERGO or OBI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBI vs. The Competition

Ondine Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools